• Most Popular
  • Most Shared

Keryx: Panel says drug candidate doesn't raise safety concerns

Thu Dec 6, 2007 8:13am EST

Stocks

   

Dec 6 (Reuters) - Keryx Biopharmaceuticals (KERX.O) said an independent data safety monitoring committee (DSMC) found no safety concerns regarding Keryx's lead drug candidate, Sulonex, for the treatment of diabetic nephropathy.

The company said the DSMC had found no reason to recommend alteration or termination of the late-stage trial. The main goal of the late-stage trial is "therapeutic success" at six months.

Diabetic nephropathy is a complication of diabetes in which the kidneys are progressively damaged. (Reporting by Neha Pathania in Bangalore; Editing by Amitha Rajan)



More from Reuters

Photo

Democrats secure 60th vote on health bill

WASHINGTON (Reuters) - Senate Democrats reached a compromise on Saturday with holdout Senator Ben Nelson that secured the 60 votes they need to pass the broad healthcare overhaul sought by President Barack Obama.

» More Top News
A woman shops at a Sam's Club store, a division of Wal-Mart Stores, in Bentonville, Arkansas June 4, 2009. REUTERS/Jessica Rinaldi

The food-stamp economy

On the last day of every month, shoppers at Walmart load their carts with food and household items and wait for the midnight hour. Is this the new normal in America?  Full Article 

U.S.
Two men shake hands in a file photo. REUTERS/File

Let's make a deal

The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis.  Full Article 

Global Deals Review